Panitumumab plus 5-fluorouracil and leucovorin (5-FU/LV) is superior to 5FU/LV alone as maintenance therapy for RAS wild-type metastatic colorectal cancer (mCRC) after induction with FOLFOX plus panitumumab, according to results from the phase 2 PANAMA trial.
The PANAMA trial, the results of which were presented at the 2021 annual meeting of the American Society of Clinical Oncology (abstract 3503), enrolled 387 patients with RAS wild-type mCRC (median age, 65.5 years; 66.5% male; ECOG